Systemic Sclerosis Associated Interstitial Lung Disease Market Size

DelveInsight's "Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Market Insights, Epidemiology and Market Forecast-2028" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of SSc-ILD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2017-2028


Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Disease Understanding and Treatment Algorithm

The DelveInsight Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market report gives the thorough understanding of the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US, EU5 and Japan.


Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology

The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology division provides the insights about historical and current patient pool and forecasted trend for all seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the total disease prevalence, diagnosed cases, treatable cases and gender specific prevalent population in the US, EU5 and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed cases and total treatable cases) scenario of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, total prevalent population of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in seven major markets was found to be 71,375 in 2017.


Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Drug Chapters

This segment of the SSc-ILD report encloses the detailed analysis of the marketed and emerging drugs. It also helps to understand the product description, clinical development, clinical trial details, approvals and other regulatory milestones, and the latest news and press releases.

At present, therapeutic approach of SSc-ILD focuses on immunosuppressant therapies. Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are the most commonly prescribed by doctors to patients having SSc-ILD. Azathioprine (AZA) and rituximab (RTX) are some other therapies that are also used. Currently, nintedanib (Boehringer Ingelheim) is the only approved drug for SSc-ILD, while pirfenidone (Beijing Continent Pharmaceutical/ Genentech) is under active investigation as potential new therapy for SSc-ILD.


Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Market Outlook

The SSc-ILD market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers.

This segment gives a thorough detail of marketed therapies and emerging therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in the 7MM was found to be USD 214.16 million in 2017.


Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Market Size by Therapies

• Key Cross Competition


Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Report Assessment

• Pipeline Product Profiles

• Key Products and Key Players

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market.

• Organize sales and marketing efforts by identifying the best opportunities for Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD).

• To understand the future market competition in the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market.

1. Key Insights

2. Systemic Sclerosis-associated Interstitial Lung Disease: Epidemiology Overview at a Glance

3. Systemic Sclerosis-associated Interstitial Lung Disease: Market Overview at a Glance

3.1. Total Market Share (%) Distribution of Systemic Sclerosis-associated Interstitial Lung Disease in 2017

3.2. Total Market Share (%) Distribution of Systemic Sclerosis-associated Interstitial Lung Disease in 2028

4. Systemic Sclerosis-associated Interstitial Lung Disease: Disease Background and Overview

4.1. Introduction

4.2. Causes

4.3. Risk Factors

4.4. Signs and Symptoms

4.5. Pathophysiology

4.6. Diagnostic Approach

4.6.1. Diagnostic algorithm for Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

4.6.2. Management of Systemic Sclerosis-associated Interstitial Lung Disease

4.6.3. Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease

5. Treatment

5.1. Current treatment for Systemic Sclerosis-associated Interstitial Lung Disease

5.2. Future treatment for Systemic Sclerosis-associated Interstitial Lung Disease

5.3. Treatment Algorithm

6. Unmet Needs

7. Organizations contributing toward SSc-ILD

8. KOL's Views: Systemic Sclerosis-associated Interstitial Lung Disease

9. Key Cross Competitors

10. Marketed Drugs

10.1. Nintedanib: Boehringer Ingelheim

10.1.1. Product Description

10.1.2. Regulatory Milestones

10.1.3. Clinical Development

10.1.4. Product Profile

10.1.5. Future development

11. Emerging Drugs

11.1. Pirfenidone: Beijing Continent Pharmaceutical/ Genentech

11.1.1. Product Description

11.1.2. Clinical Development

11.1.3. Safety and Efficacy

11.1.4. Product Profile

12. Epidemiology and Patient Population

12.1. Key Findings

13. 7MM Total Prevalent Patient Population of Systemic Sclerosis-associated Interstitial Lung Disease

14. Country Wise-Epidemiology of SSc-ILD

14.1. United States

14.1.1. Assumptions and Rationale

14.1.2. Total Prevalent Population of SSc-ILD

14.1.3. Total Gender Specific Prevalent Population of SSc-ILD

14.1.4. Total Diagnosed Cases of SSc-ILD

14.1.5. Total Treatable Cases of SSc-ILD

14.2. Europe

14.2.1. Assumptions and Rationale

14.3. Germany

14.3.1. Total Prevalent Population of SSc-ILD

14.3.2. Total Gender Specific Prevalent Population of SSc-ILD

14.3.3. Total Diagnosed Cases of SSc-ILD

14.3.4. Total Treatable Cases of SSc-ILD

14.4. France

14.4.1. Total Prevalent Population of SSc-ILD

14.4.2. Total Gender Specific Prevalent Population of SSc-ILD

14.4.3. Total Diagnosed Cases of SSc-ILD

14.4.4. Total Treatable Cases of SSc-ILD

14.5. Italy

14.5.1. Total Prevalent Population of SSc-ILD

14.5.2. Total Gender Specific Prevalent Population of SSc-ILD

14.5.3. Total Diagnosed Cases of SSc-ILD

14.5.4. Total Treatable Cases of SSc-ILD

14.6. Spain

14.6.1. Total Prevalent Population of SSc-ILD

14.6.2. Total Gender Specific Prevalent Population of SSc-ILD

14.6.3. Total Diagnosed Cases of SSc-ILD

14.6.4. Total Treatable Cases of SSc-ILD

14.7. The United Kingdom

14.7.1. Total Prevalent Population of SSc-ILD

14.7.2. Total Gender Specific Prevalent Population of SSc-ILD

14.7.3. Total Diagnosed Cases of SSc-ILD

14.7.4. Total Treatable Cases of SSc-ILD

14.8. Japan

14.8.1. Assumptions and Rationale

14.8.2. Total Prevalent Population of SSc-ILD

14.8.3. Total Gender Specific Prevalent Population of SSc-ILD

14.8.4. Total Diagnosed Cases of SSc-ILD

14.8.5. Total Treatable Cases of SSc-ILD

15. Systemic Sclerosis-associated Interstitial Lung Disease: 7 Major Market Analysis

15.1. Key Findings

15.2. Market Size of Systemic Sclerosis-associated Interstitial Lung Disease in 7MM

15.2.1. Total Market Size of Systemic Sclerosis-associated Interstitial Lung Disease

15.2.2. Market Size of Systemic Sclerosis-associated Interstitial Lung Disease by Therapies

16. United States Market Outlook

16.1. United States Market Size

16.1.1. Total Market Size of Systemic Sclerosis-associated Interstitial Lung Disease

16.1.2. Market Size of Systemic Sclerosis-associated Interstitial Lung Disease by Therapies

17. EU-5 Countries: Market Outlook

17.1. Germany

17.1.1. Total Market size of Systemic Sclerosis-associated Interstitial Lung Disease

17.1.2. Market Size of Systemic Sclerosis-associated Interstitial Lung Disease by Therapies

17.2. France

17.2.1. Total Market Size of Systemic Sclerosis-associated Interstitial Lung Disease

17.2.2. Market Size of Systemic Sclerosis-associated Interstitial Lung Disease by Therapies

17.3. Italy

17.3.1. Total Market Size of Systemic Sclerosis-associated Interstitial Lung Disease

17.3.2. Market Size of Systemic Sclerosis-associated Interstitial Lung Disease by Therapies

17.4. Spain

17.4.1. Total Market Size of Systemic Sclerosis-associated Interstitial Lung Disease

17.4.2. Market Size of Systemic Sclerosis-associated Interstitial Lung Disease by Therapies

17.5. United Kingdom

17.5.1. Total Market Size of Systemic Sclerosis-associated Interstitial Lung Disease

17.5.2. Market Size of Systemic Sclerosis-associated Interstitial Lung Disease by Therapies

18. Japan: Market Outlook

18.1. Total Market Size of Systemic Sclerosis-associated Interstitial Lung Disease

18.2. Market Size of Systemic Sclerosis-associated Interstitial Lung Disease by Therapies

19. Case Reports

19.1. Scleroderma-related interstitial lung disease: reporting four cases of SSc-ILD in the US

19.2. Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension - Case report of a Japanese woman

19.3. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease

20. Market Drivers

21. Market Barriers

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

Table 1 Quantitative and semi-quantitative scoring for SSc-ILD through HRCT: Wells et al.

Table 2 High-resolution computed tomography advantages and drawbacks

Table 3 Main biomarkers associated with SSc-ILD

Table 4 Main biomarkers associated with SSc-ILD

Table 5 Organizations contributing toward SSc-ILD

Table 6 Key Cross Competitors

Table 7 Clinical Trial Description - Nintedanib

Table 8 Pirfenidone , Clinical Trial Description, 2019

Table 9 Total Prevalent Population of SSc-ILD in the 7MM (2017-2028)

Table 10 Total Prevalent Population of SSc-ILD in the US (2017-2028)

Table 11 Gender specific prevalent population of SSc-ILD in the US (2017-2028)

Table 12 Diagnosed cases of SSc-ILD in the US (2017-2028)

Table 13 Treatable cases of SSc-ILD in the US (2017-2028)

Table 14 Total Prevalent Population of SSc-ILD in Germany (2017-2028)

Table 15 Gender specific prevalent population of SSc-ILD in Germany (2017-2028)

Table 16 Diagnosed cases of SSc-ILD in Germany (2017-2028)

Table 17 Treatable cases of SSc-ILD in Germany (2017-2028)

Table 18 Total Prevalent Population of SSc-ILD in France (2017-2028)

Table 19 Gender specific prevalent population of SSc-ILD in France (2017-2028)

Table 20 Diagnosed cases of SSc-ILD in France (2017-2028)

Table 21 Treatable cases of SSc-ILD in France (2017-2028)

Table 22 Total Prevalent Population of SSc-ILD in Italy (2017-2028)

Table 23 Gender specific prevalent population of SSc-ILD in Italy (2017-2028)

Table 24 Diagnosed cases of SSc-ILD in Italy (2017-2028)

Table 25 Treatable cases of SSc-ILD in Italy (2017-2028)

Table 26 Total Prevalent Population of SSc-ILD in Spain (2017-2028)

Table 27 Gender specific prevalent population of SSc-ILD in Spain (2017-2028)

Table 28 Diagnosed cases of SSc-ILD in Spain (2017-2028)

Table 29 Treatable cases of SSc-ILD in Spain (2017-2028)

Table 30 Total Prevalent Population of SSc-ILD in the UK (2017-2028)

Table 31 Gender specific prevalent population of SSc-ILD in the UK (2017-2028)

Table 32 Diagnosed cases of SSc-ILD in the UK (2017-2028)

Table 33 Treatable cases of SSc-ILD in the UK (2017-2028)

Table 34 Total Prevalent Population of SSc-ILD in Japan (2017-2028)

Table 35 Gender specific prevalent population of SSc-ILD in Japan (2017-2028)

Table 36 Diagnosed cases of SSc-ILD in Japan (2017-2028)

Table 37 Treatable cases of SSc-ILD in Japan (2017-2028)

Table 38 7 Major Market Size of SSc-ILD in USD Million ( 2017-2028)

Table 39 7 Major Market Size of SSc-ILD by Therapies in USD Million ( 2017-2028)

Table 40 Total Market Size of SSc-ILD in the United States (2017-2028)

Table 41 The US Market Size of SSc-ILD by Therapies in USD Million ( 2017-2028)

Table 42 Total Market Size of SSc-ILD in Germany (2017-2028)

Table 43 Germany Market Size of SSc-ILD by Therapies in USD Million ( 2017-2028)

Table 44 Total Market Size of SSc-ILD in France (2017-2028)

Table 45 France Market Size of SSc-ILD by Therapies in USD Million ( 2017-2028)

Table 46 Total Market Size of SSc-ILD in Italy (2017-2028)

Table 47 Italy Market Size of SSc-ILD by Therapies in USD Million ( 2017-2028)

Table 48 Total Market Size of SSc-ILD in Spain (2017-2028)

Table 49 Spain Market Size of SSc-ILD by Therapies in USD Million ( 2017-2028)

Table 50 Total Market Size of SSc-ILD in United Kingdom (2017-2028)

Table 51 UK Market Size of SSc-ILD by Therapies in USD Million ( 2017-2028)

Table 52 Total Market Size of SSc-ILD in Japan (2017-2028)

Table 53 Japan Market Size of SSc-ILD by Therapies in USD Million ( 2017-2028)

Figure 1 Total Prevalent Population of SSc-ILD in the 7 MM (2017)

Figure 2 Total Prevalent Population of SSc-ILD in the 7 MM (2028)

Figure 3 Total Market Share (%) Distribution of SSc-ILD in 2017

Figure 4 Total Market Share (%) Distribution of SSc-ILD in 2028

Figure 5 Causes of SSc-ILD

Figure 6 Histological sections of normal lung tissue and lung tissue with ILD

Figure 7 Risk Factors of SSc- ILD

Figure 8 Symptoms associated with SSc-ILD

Figure 9 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

Figure 10 Diagnostic algorithm for SSc-ILD

Figure 11 Management of SSc-ILD

Figure 12 Management of SSc-ILD

Figure 13 Treatment: Systemic Sclerosis-associated Interstitial Lung Disease

Figure 14 Future Treatment for SSc-ILD

Figure 15 Treatment Algorithm: Systemic Sclerosis-associated Interstitial Lung Disease

Figure 16 Unmet Needs of Systemic Sclerosis-associated Interstitial Lung Disease

Figure 17 Mechanism of action of Nintedanib

Figure 18 Regulatory Milestones of Nintedanib

Figure 19 Clinical Development of Nintedanib

Figure 20 Total Prevalent Patient Population of SSc-ILD in the 7MM (2017-2028)

Figure 21 Total Prevalent Population of SSc-ILD in the US (2017-2028)

Figure 22 Gender specific prevalent population of SSc-ILD in the US (2017-2028)

Figure 23 Diagnosed cases of SSc-ILD in the US (2017-2028)

Figure 24 Treatable cases of SSc-ILD in the US (2017-2028)

Figure 25 Total Prevalent Population of SSc-ILD in Germany (2017-2028)

Figure 26 Gender specific prevalent population of SSc-ILD in Germany (2017-2028)

Figure 27 Diagnosed cases of SSc-ILD in Germany (2017-2028)

Figure 28 Treatable cases of SSc-ILD in Germany (2017-2028)

Figure 29 Total Prevalent Population of SSc-ILD in France (2017-2028)

Figure 30 Gender specific prevalent population of SSc-ILD in France (2017-2028)

Figure 31 Diagnosed cases of SSc-ILD in France (2017-2028)

Figure 32 Treatable cases of SSc-ILD in France (2017-2028)

Figure 33 Total Prevalent Population of SSc-ILD in Italy (2017-2028)

Figure 34 Gender specific prevalent population of SSc-ILD in Italy (2017-2028)

Figure 35 Diagnosed cases of SSc-ILD in Italy (2017-2028)

Figure 36 Treatable cases of SSc-ILD in Italy (2017-2028)

Figure 37 Total Prevalent Population of SSc-ILD in Spain (2017-2028)

Figure 38 Gender specific prevalent population of SSc-ILD in Spain (2017-2028)

Figure 39 Diagnosed cases of SSc-ILD in Spain (2017-2028)

Figure 40 Treatable cases of SSc-ILD in Spain (2017-2028)

Figure 41 Total Prevalent Population of SSc-ILD in the UK (2017-2028)

Figure 42 Gender specific prevalent population of SSc-ILD in the UK (2017-2028)

Figure 43 Diagnosed cases of SSc-ILD in the UK (2017-2028)

Figure 44 Treatable cases of SSc-ILD in the UK (2017-2028)

Figure 45 Total Prevalent Population of SSc-ILD in Japan (2017-2028)

Figure 46 Gender specific prevalent population of SSc-ILD in Japan (2017-2028)

Figure 47 Diagnosed cases of SSc-ILD in Japan (2017-2028)

Figure 48 Treatable cases of SSc-ILD in Japan (2017-2028)

Figure 49 7 Major Market Size of SSc-ILD in USD Million ( 2017-2028)

Figure 50 7 Major Market Size of SSc-ILD by Therapies in USD Million (2017-2028)

Figure 51 The United States Market Size of SSc-ILD in USD Million ( 2017-2028)

Figure 52 The US Market Size of SSc-ILD by Therapies in USD Million (2017-2028)

Figure 53 Market Size of SSc-ILD in Germany, USD Million (2017-2028)

Figure 54 Germany Market Size of SSc-ILD by Therapies in USD Million (2017-2028)

Figure 55 Market Size of SSc-ILD in France USD Million ( 2017-2028)

Figure 56 France Market Size of SSc-ILD by Therapies in USD Million ( 2017-2028)

Figure 57 Market Size of SSc-ILD in Italy, USD Million ( 2017-2028)

Figure 58 Italy Market Size of SSc-ILD by Therapies in USD Million (2017-2028)

Figure 59 Market Size of SSc-ILD in Spain, USD Million (2017-2028)

Figure 60 Spain Market Size of SSc-ILD by Therapies in USD Million (2017-2028)

Figure 61 Market Size of SSc-ILD in the United Kingdom, USD Million (2017-2028)

Figure 62 The UK Market Size of SSc-ILD by Therapies in USD Million (2017-2028)

Figure 63 Market Size of SSc-ILD in Japan, USD Million (2017-2028)

Figure 64 The Japan Market Size of SSc-ILD by Therapies in USD Million (2017-2028)

Figure 65 Market Drivers

Figure 66 Market Barriers

  • Tags:
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inter...
  • Systemic Sclerosis-associated Inte...

Forward to Friend

Need A Quote